Urinary eosinophil-derived neurotoxin is associated with reduced lung function in pediatric asthma.
T2‐high phenotype
atopy
biomarker
children
eosinophil‐derived neurotoxin
preschool wheeze
Journal
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038
Titre abrégé: Pediatr Allergy Immunol
Pays: England
ID NLM: 9106718
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
revised:
15
05
2024
received:
13
01
2024
accepted:
27
05
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
14
6
2024
Statut:
ppublish
Résumé
Eosinophil-derived neurotoxin (EDN) is a biomarker for eosinophilic activation. Urinary (u) EDN may allow non-invasive monitoring of asthma, but clinical recommendations are lacking. We assessed the potential of uEDN as a marker of disease activity in pediatric asthma. We assessed urine samples of 371 children from the German ALLIANCE study cohort, from which we had: 169 preschool wheezers (<6 years), 80 asthmatics (≥6 years), and 122 healthy controls using the ImmunoCAP™ EDN Assay. Creatinine (Cr)-adjusted uEDN values were analyzed using correlations, association tests, (non) parametric statistics, multiple linear, and multivariable regression. uEDN/uCr values were higher in atopic versus non-atopic preschool-aged subjects (p = .035) and associated with the sum of allergen-specific IgE in younger (r = 0.24, p = .003), and older subjects (r = 0.23, p = .043). uEDN/uCr was marginally a good determinant for atopy (p = .078, for subjects aged <6 years, and p = .058 for subjects ≥6 years). Children with the T2-high phenotype had higher uEDN/uCr (p < .001) versus T2-low-irrespective of using uEDN/uCr or blood eosinophils in combination to allergen sIgE for disease phenotyping. uEDN/uCr significantly correlated with reduced lung function among asthmatics (FEV uEDN/uCr may serve as a non-invasive biomarker for clinical features such as lung function in pediatric asthma. We highlight the utility of uEDN/uCr as a biomarker that can be easily assessed using widely available robust diagnostic immunoassays.
Substances chimiques
Eosinophil-Derived Neurotoxin
EC 3.1.-
Biomarkers
0
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14172Subventions
Organisme : CS is supported by the Universities Giessen and Marburg Lung Center (UGMLC), the German Center for Lung Research (DZL), University Hospital Giessen and Marburg (UKGM) research funding according to article 2, section 3 cooperation agreement, and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)-SFB 1021
ID : 197785619
Organisme : KFO 309
ID : 284237345
Organisme : SK 317/1-1
ID : 428518790
Organisme : German Research Foundation
ID : SCHA 997/9-1
Organisme : German Research Foundation
ID : SCHA 997/10-1
Organisme : German Research Foundation
ID : SCHA 997/11-1
Informations de copyright
© 2024 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Asher MI, Garcia‐Marcos L, Pearce NE, Strachan DP. Trends in worldwide asthma prevalence. Eur Respir J. 2020;56(6):2002094. doi:10.1183/13993003.02094-2020
Asher MI, Rutter CE, Bissell K, et al. Worldwide trends in the burden of asthma symptoms in school‐aged children: global asthma network phase I cross‐sectional study. Lancet. 2021;398(10311):1569‐1580. doi:10.1016/S0140-6736(21)01450-1
Aaron SD, Boulet LP, Reddel HK, Gershon AS. Underdiagnosis and Overdiagnosis of asthma. Am J Respir Crit Care Med. 2018;198(8):1012‐1020. doi:10.1164/rccm.201804-0682CI
Reddel HK, Bacharier LB, Bateman ED, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Am J Respir Crit Care Med. 2022;205(1):17‐35. doi:10.1164/rccm.202109-2205PP
Kim CK, Callaway Z, Park JS, Kwon E. Utility of serum eosinophil‐derived neurotoxin (EDN) measurement by ELISA in young children with asthma. Allergol Int. 2017;66(1):70‐74. doi:10.1016/j.alit.2016.05.008
Wechsler ME, Munitz A, Ackerman SJ, et al. Eosinophils in health and disease: a state‐of‐the‐art review. Mayo Clin Proc. 2021;96(10):2694‐2707. doi:10.1016/j.mayocp.2021.04.025
Koller DY, Halmerbauer G, Frischer T, Roithner B. Assessment of eosinophil granule proteins in various body fluids: is there a relation to clinical variables in childhood asthma? Clin Exp Allergy. 1999;29(6):786‐793. doi:10.1046/j.1365-2222.1999.00546.x
Kim KW, Lee KE, Kim ES, Song TW, Sohn MH, Kim KE. Serum eosinophil‐derived neurotoxin (EDN) in diagnosis and evaluation of severity and bronchial hyperresponsiveness in childhood asthma. Lung. 2007;185(2):97‐103. doi:10.1007/s00408-006-0054-8
Goto T, Morioka J, Inamura H, et al. Urinary eosinophil‐derived neurotoxin concentrations in patients with atopic dermatitis: a useful clinical marker for disease activity. Allergol Int. 2007;56(4):433‐438. doi:10.2332/allergolint.O-07-489
Nuijsink M, Hop WC, Sterk PJ, et al. Urinary eosinophil protein X in children with atopic asthma. Mediat Inflamm. 2007;2007:49240. doi:10.1155/2007/49240
Oymar K. High levels of urinary eosinophil protein X in young asthmatic children predict persistent atopic asthma. Pediatr Allergy Immunol. 2001;12(6):312‐317. doi:10.1034/j.1399-3038.2001.0o080.x
Terashi Y, Kim CK, Callaway Z, et al. Natural history of eosinophil‐derived neurotoxin levels and the onset of allergic airway disease in preschool children. Exp Ther Med. 2023;26(6):565. doi:10.3892/etm.2023.12264
Kim CK, Callaway Z, Fletcher R, Koh YY. Eosinophil‐derived neurotoxin in childhood asthma: correlation with disease severity. J Asthma. 2010;47(5):568‐573. doi:10.3109/02770901003792833
Fardig M, Lie A, Borres MP, et al. Eosinophil‐derived neurotoxin levels in early childhood and association with preschool asthma – a prospective observational study. Clin Exp Allergy. 2023;53:1198‐1211. doi:10.1111/cea.14409
Koller DY. Sampling methods: urine/blood analysis. Am J Respir Crit Care Med. 2000;162(2 Pt 2):S31‐S33. doi:10.1164/ajrccm.162.supplement_1.maic-8
Maison N, Omony J, Illi S, et al. T2‐high asthma phenotypes across lifespan. Eur Respir J. 2022;60(3):2102288. doi:10.1183/13993003.02288-2021
Global Strategy for Asthma Management and Prevention. GINA Guideline Version 1.3. 2011.
(BÄK) GMA. National Association of Statutory Health Insurance Physicians (KBV), Working Group of Scientific Medical Societies (AWMF). Nationale VersorgungsLeitlinie Asthma – Langfassung National Asthma Care Guideline – Long Version. 2020 Version 1(4. Auflage).
Fuchs O, Bahmer T, Weckmann M, et al. The all age asthma cohort (ALLIANCE) ‐ from early beginnings to chronic disease: a longitudinal cohort study. BMC Pulm Med. 2018;18(1):140. doi:10.1186/s12890-018-0705-6
Tang KW, Toh QC, Teo BW. Normalisation of urinary biomarkers to creatinine for clinical practice and research—when and why. Singapore Med J. 2015;56(1):7‐10. doi:10.11622/smedj.2015003
Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319‐338. doi:10.1183/09031936.05.00034805
Cooper BG, Stocks J, Hall GL, et al. The global lung function initiative (GLI) network: bringing the world's respiratory reference values together. Breathe (Sheff). 2017;13(3):e56‐e64. doi:10.1183/20734735.012717
Skevaki C, Tafo P, Eiringhaus K, et al. Allergen extract‐ and component‐based diagnostics in children of the ALLIANCE asthma cohort. Clin Exp Allergy. 2021;51(10):1331‐1345. doi:10.1111/cea.13964
Bedolla‐Barajas M, Morales‐Romero J, Hernandez‐Colin DD, et al. Beyond eosinophilia: inflammatory patterns in patients with asthma. J Asthma. 2022;59(2):255‐263. doi:10.1080/02770903.2020.1852413
Malinovschi A, Rydell N, Fujisawa T, Borres MP, Kim CK. Clinical potential of eosinophil‐derived neurotoxin in asthma management. J Allergy Clin Immunol Pract. 2022;11:750‐761. doi:10.1016/j.jaip.2022.11.046
Rutten B, Young S, Rhedin M, et al. Eosinophil‐derived neurotoxin: a biologically and analytically attractive asthma biomarker. PLoS One. 2021;16(2):e0246627. doi:10.1371/journal.pone.0246627
Ban GY, Yang EM, Ye YM, Park HS. Association of eosinophil‐derived neurotoxin levels with asthma control status in patients with aspirin‐exacerbated respiratory disease. Clin Transl Allergy. 2023;13(3):e12229. doi:10.1002/clt2.12229
Chiu CY, Tsai MH, Yao TC, et al. Urinary LTE4 levels as a diagnostic marker for IgE‐mediated asthma in preschool children: a birth cohort study. PLoS One. 2014;9(12):e115216. doi:10.1371/journal.pone.0115216
Chawes BL, Bonnelykke K, Bisgaard H. Elevated eosinophil protein X in urine from healthy neonates precedes development of atopy in the first 6 years of life. Am J Respir Crit Care Med. 2011;184(6):656‐661. doi:10.1164/rccm.201101-0111OC
Badar A, Hussain MM, Saeed W, Aslam M. Correlation of eosinophil derived neurotoxin with airway resistance in asthmatics. J Pak Med Assoc. 2010;60(2):97‐101.
Hoekstra MO, Hovenga H, Gerritsen J, Kauffman HF. Eosinophils and eosinophil‐derived proteins in children with moderate asthma. Eur Respir J. 1996;9(11):2231‐2235. doi:10.1183/09031936.96.09112231
Kim CK, Callaway Z, Kim DW, Kita H. Eosinophil degranulation is more important than eosinophilia in identifying asthma in chronic cough. J Asthma. 2011;48(10):994‐1000. doi:10.3109/02770903.2011.623335
Kim HS, Yang HJ, Song DJ, et al. Eosinophil‐derived neurotoxin: an asthma exacerbation biomarker in children. Allergy Asthma Proc. 2022;43(2):133‐139. doi:10.2500/aap.2022.43.210001
Matricardi PM, Dramburg S, Potapova E, Skevaki C, Renz H. Molecular diagnosis for allergen immunotherapy. J Allergy Clin Immunol. 2019;143(3):831‐843. doi:10.1016/j.jaci.2018.12.1021